Name: BIM-IOL System in Open-angle glaucoma or ocular hypertension: Generic, brand name and therapeutic class of product
Published: 2026-09-17T18:17:42-04:00

Product information and disease description Product description Product information

Generic, brand name and therapeutic class of product

3 evidence topics · 2 sources

Manufacturer: SpyGlass Pharma

“SpyGlass Pharma, Inc.” (opens the source at this quote in a new tab)

Product names

“SpyGlass Pharma’s lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary non-bioerodible drug pads attached to its intraocular lens, was designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).” (opens the source at this quote in a new tab)

Registry field	Quoted record
Intervention name	“Bimatoprost Implant System”
Intervention description	“Bimatoprost Implant System used in combination with the SpyGlass IOL”
Device intervention	“SpyGlass Intraocular Lens”

Therapeutic class of the active ingredient

“The BIM-IOL System is designed to consistently deliver three years of bimatoprost, a prostaglandin analog approved for topical use by the U.S. Food and Drug Administration (FDA) in 2001, for the reduction of elevated IOP in patients with OAG or OHT.” (opens the source at this quote in a new tab)

Proprietary (brand) name

No evidence found.